-

03:01:28 AM

FNCH Stock News

FNCH - Finch Therapeutics Group Inc

01/24/23 8:00 AM

Nasdaq : FNCH

clinical trial

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the

RHEA-AI

neutral

11/10/22 7:00 AM

Nasdaq : FNCH

earnings

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a

RHEA-AI

neutral

11/09/22 8:00 AM

Nasdaq : FNCH

conferences

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,

RHEA-AI

neutral

10/24/22 8:00 AM

Nasdaq : FNCH

clinical trial

Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,

RHEA-AI

neutral

09/01/22 8:00 AM

Nasdaq : FNCH

Finch Therapeutics Provides Business Update

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,

RHEA-AI

neutral

08/25/22 4:30 PM

Nasdaq : FNCH

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,

RHEA-AI

neutral

08/11/22 7:00 AM

Nasdaq : FNCH

earnings

Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 Additional results from PRISM-EXT Phase 2 trial of CP101 in recurrent CDI accepted for presentation at

RHEA-AI

neutral

06/02/22 7:00 AM

Nasdaq : FNCH

conferences

Finch Therapeutics to Participate in Upcoming June Investor Conferences

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,

RHEA-AI

neutral

05/17/22 8:00 AM

Nasdaq : FNCH

conferences

Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,

RHEA-AI

neutral

05/16/22 7:00 AM

Nasdaq : FNCH

earnings

Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

FDA lifted clinical hold on IND for CP101 Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 $15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024 Corporate update call today at 8am ET SOMERVILLE, Mass., May 16, 2022

RHEA-AI

neutral

FNCH Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitefinchtherapeutics.com
Security nameFinch Therapeutics Group Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees189

About Finch Therapeutics Group Inc

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.